Zandi P, Panis Y, Debray D, Bernard O, Houssin D
Clinique Chirurgicale, Hôpital Cochin, Paris, France.
Hepatology. 1995 Jan;21(1):129-33.
Langerhans' cell histiocytosis (LCH) represents 15% to 20% of sclerosing cholangitis (SC) in children. In LCH-associated SC, a very poor response to chemotherapy has been reported, and spontaneous prognosis is very bad. Few cases of orthotopic liver transplantation (OLT) for LCH have been reported and little is known about the risk of recurrence and the effect of immunosuppression after OLT. Since 1986, five children (mean age +/- SD, 12.6 +/- 3.6 years) underwent OLT for SC complicating LCH. All patients presented with growth retardation, and severe liver disease including repeated episodes of variceal bleeding (n = 5), liver insufficiency (n = 4), jaundice (n = 5), and ascitis (n = 4). Four patients presented with previous abdominal surgery (mesocaval shunt in two and explorative laparotomy in two). OLT was performed using a whole (n = 2) or a reduced liver graft (n = 3). Pathological examination of the recipient liver showed biliary cirrhosis in all cases. Three patients are alive and well 9 to 88 months after OLT. None presented with recurrence of LCH or SC within the liver graft or in other organs. General condition (including growth and puberty) improved dramatically in the three surviving patients. Absence of recurrence after up to 7 years of follow-up after liver transplantation in our patients, as well as in all other reported cases, is encouraging and shows that OLT may be indicated in end-stage liver disease complicating LCH. Furthermore, cyclosporine may be beneficial for preventing recurrence of LCH, in which autoimmunologic mechanisms have been advocated.
朗格汉斯细胞组织细胞增多症(LCH)占儿童硬化性胆管炎(SC)的15%至20%。在LCH相关的SC中,据报道对化疗反应很差,且自然预后非常糟糕。关于LCH原位肝移植(OLT)的病例报道很少,对OLT后复发风险和免疫抑制效果了解甚少。自1986年以来,5名儿童(平均年龄±标准差,12.6±3.6岁)因LCH合并SC接受了OLT。所有患者均有生长发育迟缓,以及严重肝病,包括反复发生静脉曲张出血(5例)、肝功能不全(4例)、黄疸(5例)和腹水(4例)。4例患者曾接受过腹部手术(2例行肠系膜上腔静脉分流术,2例行剖腹探查术)。OLT采用全肝移植(2例)或减体积肝移植(3例)。受体肝脏的病理检查显示所有病例均为胆汁性肝硬化。3例患者在OLT后9至88个月存活且状况良好。肝移植肝内或其他器官均未出现LCH或SC复发。3名存活患者的一般状况(包括生长发育和青春期)显著改善。我们的患者以及所有其他报道病例在肝移植后长达7年的随访中均未出现复发,这令人鼓舞,表明OLT可能适用于LCH合并的终末期肝病。此外,环孢素可能有助于预防LCH复发,其中自身免疫机制已得到支持。